ARGUABLY one of Australia's great industry success stories, global biotech company CSL presented its credentials at the JP Morgan Conference 2019 on Wed.
CSL CEO and MD Paul Perreault presented the company as the fifth largest global biotech in the world.
He claimed number one position in the $30 billion plasma therapies market and number two ranking in the $6 billion global influenza vaccines industry.
CSL can now boast significant business success in more than 60 countries with revenues totalling approximately $8 billion.
The company has eight major manufacturing sites spread across six countries, a major capacity expansion program underway and a deep research and development pipeline to fuel future growth, Perrault said.
Overall, the company's strong financial position is exemplified by its net debt to earnings (EBITDA) ratio of 1.3:1 resulting in an A+/A credit rating (stable/stable).
CSL operates across three main therapeutic platforms: plasma fractionation, recombinant technology and gene and cell therapy, touching on immunology and neurology, haematology and thrombosis, transplant, respiratory function as well as cardiovascular and metabolic issues.
The Seqirus vaccines division is the only globally scaled maker of cell culture vaccines.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Jan 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Jan 19
